Skip to search formSkip to main contentSkip to account menu

caracemide

Known as: Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI), Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI), N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea 
An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryForty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with… 
2004
2004
Twenty-four previously untreated, ambulatory patients with advanced colorectal carcinoma were treated with either caracemide (11… 
2004
2004
SummaryA Phase I study of caracemide evaluating a short intravenous infusion repeated every 21 days is presented. Patients were… 
2004
2004
Caracemide (NacetylN(methylcarbamoyloxy)N-methylurea) is a nonspecific inhibitor of macromolecular synthesis [1]. It has in vitro… 
1993
1993
Following administration to rats of a single ip dose (6.6 mg kg-1) of the investigational antitumor agent caracemide (N-acetyl-N… 
1990
1990
The antitumor agent caracemide [N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea] has been observed to induce signs of cholinergic… 
1988
1988
The cytotoxic effect of caracemide and hydroxyurea was compared in human chronic myeloid leukemia cells. Caracemide was found to… 
1987
1987
We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon… 
1984
1984
: Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from…